Napo Pharmaceuticals provides fiscal support for ACE survey

In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo Pharmaceuticals, a Jaguar Health family company, announced they were proud to provide fiscal support for “More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.” The online, anonymous survey was an initiative of Advocates for Collaborative Education. The survey received over 500 responses and will offer a unique perspective on the experiences and priorities of those affected by cancer. “While cancer treatments have advanced considerably since the advent and availability of targeted therapies, significant short- and long-term treatment side effects can be challenging or even devastating to an individual’s quality of life,” said Advocates for Collaborative Education founder Stacey Tinianov, MPH. “Our goal was to move beyond progression-free survival and overall survival statistics to quantify quality-of-life impacts across a large sampling of individuals with a diagnosis or history of cancer. We were thrilled to have Napo’s support and hope these findings will inform research, clinical care, and the broader cancer community on what matters most to individuals and, potentially, how best to address quality-of-life impacts through improvements in supportive care.”